PT  - JOURNAL ARTICLE
AU  - Lawton, Michael
AU  - Ben-Shlomo, Yoav
AU  - Gkatzionis, Apostolos
AU  - Hu, Michele T.
AU  - Grosset, Donald
AU  - Tilling, Kate
TI  - Two sample Mendelian Randomisation using an outcome from a multilevel model of disease progression
AID  - 10.1101/2023.04.27.23289203
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.27.23289203
4099  - http://medrxiv.org/content/early/2023/05/02/2023.04.27.23289203.short
4100  - http://medrxiv.org/content/early/2023/05/02/2023.04.27.23289203.full
AB  - Identifying factors that are causes of disease progression, especially in neurodegenerative diseases, is of considerable interest. Disease progression can be described as a trajectory of outcome over time - for example, a linear trajectory having both an intercept (severity at time zero) and a slope (rate of change). A technique for identifying causal relationships between one exposure and one outcome in observational data whilst avoiding bias due to confounding is two sample Mendelian Randomisation (2SMR). We consider a multivariate approach to 2SMR using a multilevel model for disease progression to estimate the causal effect an exposure has on the intercept and slope. We carry out a simulation study comparing a naïve univariate 2SMR approach to a multivariate 2SMR approach with one exposure that effects both the intercept and slope of an outcome that changes linearly with time since diagnosis. The simulation study results for both approaches were similar and approximately unbiased (bias for intercept ranges from -1.6% to 1.5% and the slope -0.7% to 4.1%) with appropriate coverage of the 95% confidence intervals (for intercept 94.1%-96.2% and the slope 94.7%-96.0%). The multivariate approach gives a better joint coverage of both the intercept and slope effects (93.3%-95.8% for multivariate approach compared to 89.0%-92.5% for the naïve approach). We also apply our method to two Parkinson’s cohorts to examine the effect body mass index has on disease progression. There was no strong evidence that BMI affects disease progression, however the confidence intervals for both intercept and slope were wide.Competing Interest StatementMichael Lawton received fees for advising on a secondary analysis of an RCT sponsored by North Bristol NHS trust. Michele T.M. Hu received funding/grant support from Parkinsons UK, Oxford NIHR BRC, University of Oxford, CPT, Lab10X, NIHR, Michael J Fox Foundation, H2020 European Union, GE Healthcare and the PSP Association. She also received payment for Advisory Board attendance/consultancy for Lundbeck, ESCAPE Bio, Evidera, Manus Neurodynamica, Biogen MA, CuraSen Therapeutics, Roche Products Ltd. She is an advisory founder of NeuHealth Digital Ltd (company number: 14492037), a digital biomarker platform to remotely manage condition progression for Parkinsons. Donald G Grosset received payment for advisory board attendance from BIAL Pharma, Britannia Pharmaceuticals, and consultancy fees from the GM clinic. Grant support from Parkinsons UK, the Neurosciences Foundation, and Michaels Movers. Funding StatementBoth the Oxford Discovery (grant reference J-1403) and Tracking Parkinsons (PRoBaND) cohorts (grant reference J-1101) were funded by Parkinsons UK. KT and AG work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council and the University of Bristol (MC_UU_00011/3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Oxford Discovery cohort was approved by NRES Committee, South Central Oxford A Research Ethics Committee, Reference number 16/SC/0108 The Tracking Parkinsons cohort was approved by West of Scotland Research Ethics Service (WoSRES) reference 11/AL/0163 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes